Portfolio Snapshots

We are an international equities manager, and we invest with a truly global outlook.

Here is a snapshot of the current portfolio disposition of our flagship Platinum Trust Funds and their key holdings.

Platinum International Health Care Fund

Platinum International Health Care Fund invests in health care companies from around the world, ranging from those engaged in early exploratory research to those providing health care services directly to consumers.

Established in 2003, the fund now has A$568.3 million under management^ and a track record of achieving 11.6% compound return annually since inception (on 10/11/2003).*

Platinum International Health Care Fund provides exposure to companies engaged in the provision of a wide range of products and services within the global healthcare ecosystem. It invests in multinational pharmaceuticals as well as emerging biotechs with cutting-edge R&D; hospital chains and nursing care operators as well as providers of diagnostic and laboratory technologies; health insurers as well as healthcare software providers.

Industry Breakdown1
SectorLong % Short %Net %
Health Care 82.4 (2.6) 79.8
Industrials 0.5 - 0.5
Information Technology 0.4 - 0.4
Top 10 Positions3
StockCountryIndustry%
Almirall SA Spain Pharmaceuticals 2.4
Bayer AG Germany Pharmaceuticals 2.8
CStone Pharmaceuticals China Biotechnology 2.1
Esperion Therapeutics Inc United States of America Biotechnology 1.9
Gilead Sciences Inc United States of America Biotechnology 2.0
Kazia Therapeutics Ltd Australia Biotechnology 2.1
Sanofi SA France Pharmaceuticals 3.6
SpeeDx Pty Ltd Australia Biotechnology 3.0
Takeda Pharmaceutical Co Japan Pharmaceuticals 3.7
Telix Pharmaceuticals Ltd Australia Biotechnology 2.1
Total 25.7
Disposition of Assets2
Long %Short %Net %Currency%
Asia-Pacific 25.0 - 25.0 30.8
Australia 9.5 - 9.5 11.5
China 8.8 - 8.8 8.8
Hong Kong 0.9 - 0.9 0.9
Japan 4.7 - 4.7 4.3
New Zealand 0.8 - 0.8 0.8
Singapore 0.4 - 0.4 0.4
China Renminbi Offshore - - - 4.1
Europe 24.1 - 24.1 22.2
Belgium 2.3 - 2.3 -
Denmark 0.9 - 0.9 0.9
France 4.1 - 4.1 -
Germany 9.9 - 9.9 -
Ireland 0.7 - 0.7 -
Netherlands 1.0 - 1.0 -
Spain 2.4 - 2.4 -
Switzerland 1.0 - 1.0 1.0
United Kingdom 1.7 - 1.7 4.8
Euro - - - 15.4
North America 34.2 (2.6) 31.6 47.1
Canada 0.8 - 0.8 0.8
United States of America 33.4 (2.6) 30.8 46.3
Sub-Total 83.3 (2.6) 80.7 100.0
Cash 16.7 - 19.3 -
Total 100.0 - 100.0 100.0
Long - 86 stocks, 2 options Short - 2 swaps
Top 10 Positions3
StockCountryIndustry%
Almirall SA Spain Pharmaceuticals 2.4
Bayer AG Germany Pharmaceuticals 2.8
CStone Pharmaceuticals China Biotechnology 2.1
Esperion Therapeutics Inc United States of America Biotechnology 1.9
Gilead Sciences Inc United States of America Biotechnology 2.0
Kazia Therapeutics Ltd Australia Biotechnology 2.1
Sanofi SA France Pharmaceuticals 3.6
SpeeDx Pty Ltd Australia Biotechnology 3.0
Takeda Pharmaceutical Co Japan Pharmaceuticals 3.7
Telix Pharmaceuticals Ltd Australia Biotechnology 2.1
Total 25.7
All data as at [31 March 2021] .
  1. “Long %” represents the Fund’s effective exposures to the relevant sectors as a percentage of the Fund’s NAV, taking into account direct stock holdings and long derivative positions (stocks and indices). “Net %” represents the Fund’s net exposures to the relevant sectors as a percentage of the Fund’s NAV, taking into account direct stock holdings and both long and short derivative positions (stocks and indices).
  2. “Long %” represents the Fund’s effective exposures to the relevant regions as a percentage of NAV through stock holdings and long derivatives (stocks and indices). “Net %” represents the Fund’s net exposures to the relevant regions as a percentage of NAV through stock holdings and both long and short derivatives (stocks and indices). “Currency %” represents the Fund’s effective exposures to the relevant currencies as a percentage of NAV through stock holdings, cash and the use of derivatives.
  3. The “Top 10 Positions” table shows the Fund’s top 10 long stock positions as a percentage of the Fund's NAV, taking into account direct stock holdings and long derivative positions.